编者按：在2026年SGO年会上，由韩国妇科肿瘤学会（KSGO）、日本妇科肿瘤学会（JSGO）与美国妇科肿瘤学会（SGO）联合举办的卵巢癌专场，围绕晚期卵巢癌的治疗策略与前沿进展展开深入研讨。本场会议由Jessica Ji Son医生（得克萨斯肿瘤中心-迪克·斯雷顿癌症中心）担任协调人，由日本JSGO的Yusuke Kobayashi医生（庆应义塾大学）、美国SGO的Melissa Pham医生（加州大学戴维斯分校健康中心）及韩国KSGO的Dong Hoon Suh医生（首尔大学盆唐医院）共同主持。

 

本次联合专场分为三个环节，旨在推动三国妇科肿瘤医师在手术理念与前沿药物应用方面的经验互鉴。核心内容如下：

手术专场：纪念斯隆-凯特琳癌症中心的Dennis Chi医生基于TRUST试验最新数据，重新审视了初始肿瘤细胞减灭术（PDS）与新辅助化疗联合间歇性肿瘤细胞减灭术（NACT-IDS）的优效之争；里诺希望中心的Peter Lim医生探讨了机器人手术在晚期卵巢癌减灭术中的应用前景；亚洲大学医院的Suk-Joon Chang医生介绍了腹腔热灌注化疗（HIPEC）的应用进展。随后，本环节进入专家讨论。

 

全身治疗专场：埼玉医科大学国际医疗中心的Kosuke Shigematsu医生围绕PARP抑制剂、免疫检查点抑制剂（ICI）、贝伐珠单抗及抗体药物偶联物（ADC）等药物，探讨了晚期卵巢癌的个体化治疗选择与临床用药顺序；伊诺瓦·沙尔癌症研究所的Leslie Randall医生报告了ADC药物Elahere（mirvetuximab soravtansine）在铂耐药卵巢癌中的真实世界疗效与安全性数据。来自韩国和日本的青年医生代表分享了各自地区的药物可及性差异及临床实践经验。

 

多学科病例讨论：首尔大学医学院的Hyun-Ji Lim医生和日本国立癌症中心医院的Taro Yamanaka医生作为代表，分享了多学科视角的病例。

 

 

本报在会议现场特别采访了Melissa Pham医生、Dong Hoon Suh医生和Jessica Ji Son医生，就KSGO-JSGO-SGO联合专场的设计理念、学术焦点及跨国协作的临床启示进行了交流。

 

Melissa Pham：从美方角度来说，KSGO-JSGO-SGO联合专场是一项完全协作的成果。今年的KSGO-JSGO-SGO联合专场的主题围绕手术和全身化疗，着眼于抗体药物偶联物（ADC）及其他靶向治疗的最新进展，因此我们着力邀请该领域当前活跃的专家。

 

今年的KSGO-JSGO-SGO联合专场的第一个板块聚焦外科，我们有幸请到了Dennis Chi医生和Peter Lim医生。Leslie Randall医生也在聚焦全身治疗的第二个板块作报告。

 

Dong Hoon Suh：关于一些涉及高新技术的话题，本专场还收到了韩国学者的投稿。本次会议参与人员众多，我们为KSGO-JSGO-SGO第三个板块“肿瘤病例讨论会”安排了两位汇报人。我们特别推举他们，是因为他们都是年轻医生。这次KSGO-JSGO-SGO联合会议的目标之一，就是尽可能多地吸引各学会所在国家的年轻医生到美国来交流。这两位讲者分别是来自日本的Taro Yamanaka医生，和来自韩国的Hyun-Ji Lim医生。

 

Jessica Ji Son：在第二个板块，我们还邀请了Kosuke Shigematsu医生作报告，他也是全身治疗方面的讲者。这样，各个学会的专家都得到了充分代表，大家贡献各自的专长，展开了富有成效的精彩讨论。

 

我们每年都会为KSGO-JSGO-SGO联合专场设定一个瘤种方向。去年的主题是子宫内膜癌，我们对此进行了深入研讨；今年则是卵巢癌。我们非常希望会议内容能够全面覆盖，并让每个学会都能参与进来，因此我们努力在各学会内部寻找该主题下的专家。

 

Oncology Frontier:The KSGO-JSGO-SGO joint session represents a collaboration between KSGO，JSGO，and SGO.How were the speakers and topics selected for this session?What roles did each society play in the selection process?

 

Melissa Pham:It was very much a collaborative effort from the American side.Given that our topic centered around surgery and systemic chemotherapy(especially with the advancements of ADCs and other targeted treatments)，we focused closely on engaging current experts in the field.On the surgical side，we were fortunate to have Dr.Dennis Chi and Dr.Peter Lim，and Dr.Leslie Randall also joined us.

 

Dong Hoon Suh：For topics involving high technology，we had submissions from Korea.With a lot of people involved，we had two presenters for the Tumor Board.We especially promoted them because they are young doctors.One of the session’s goals was recruiting as many young doctors from their own countries to the United States.One of them is Taro Yamanaka from Japan，and the other one is HyunJi Lim from Korea.

 

Jessica Ji Son:We also had a doctor Kosuke Shigematsu who was on the systemic therapy side as well.We had experts in our field that were with us from all societies being well represented to bring their expertise for a good，productive discussion.

 

We have a disease site that the KSGO-JSGO-SGO joint session focuses on every year.Last year，the topic was endometrial cancer，and we had an indepth session on that.And this year it was ovarian cancer.We very much wanted the session to be comprehensive and for there to be representation from each society.And we try to find the experts on that topic within each of our societies.

 

Melissa Pham：我们KSGO-JSGO-SGO联合专场的第一部分聚焦于外科。作为妇科肿瘤医生，我们既承担化疗的内科工作，也从事外科手术，对这两个方面都同等重视。在卵巢癌手术领域，关于新辅助化疗是否优于初始肿瘤细胞减灭术（PDS vs.NAC-IDS）的争论由来已久。本专场第一个板块的核心正是近期发表的TRUST试验，我们很幸运地请到Dennis Chi医生来作这一场报告。第二位讲者是Peter Lim医生，他专注于机器人手术，这正是他的专长所在。可以肯定地说，无论是在美国国内还是全球，机器人手术作为卵巢癌减瘤手术的工具，其充分性依然存在很大争议。

 

Jessica Ji Son：在KSGO-JSGO-SGO专场的全身治疗板块，我们围绕各国不同的药物审批环境，以及各个国家乃至患者获取这些疗法的途径和机制，展开了非常富有成效且十分有趣的讨论。这对每一位参会者来说，都是一次难得而宝贵的学习机会。今年KSGO-JSGO-SGO联合专场的第三个板块则是肿瘤病例讨论会，回顾分析了几个非常有意思的病例。

 

Oncology Frontier:Could you please introduce the topics discussed in the KSGO-JSGO-SGO joint session and explain what clinical focuses each topic addresses?

 

Melissa Pham:Our first part of KSGO-JSGO-SGO joint session focused on surgery.As gynecologic oncologists，we incorporate both the medical oncology aspect of administering chemotherapy and the surgical aspect，and we deeply value both sides of our profession.In surgery，there is an ongoing and longstanding debate regarding whether neoadjuvant chemotherapy is superior to primary debulking surgery(PDS vs.NAC-IDS).The recently published TRUST trial was the focus of the first session，and we were lucky to have Dr.Dennis Chi deliver that lecture.The second speaker was Dr.Peter Lim，who focused on robotic surgery，which is very much his area of expertise.I’m sure that across the country and around the world，robotic surgery remains highly debated in terms of its adequacy as a tool for ovarian debulking surgery.

 

Jessica Ji Son:In the systemic therapy part of the KSGO-JSGO-SGO joint session，I think we had a very productive and interesting discussion concerning the differing drug approval landscapes and the mechanisms by which each country，and subsequently the patients，gain access to these therapies.It served as a nice and valuable learning opportunity for every participant.

 

The third part of our KSGO-JSGO-SGO joint session consisted of a tumor board reviewing several interesting cases.

 

Dong Hoon Suh：毫无疑问是ADC。如今抗体药物偶联物在妇科肿瘤领域无处不在。我们也把这个话题放进了KSGO-JSGO-SGO联合专场的第二板块（即全身治疗部分），并邀请了Kosuke Shigematsu医生分享他个人的临床经验。在韩国和日本，ADC的发展尚未达到国际前沿水平，市场份额还比较小，存在一些现实限制。在将一种新药引入日常临床实践之前，我们非常希望能听到经验丰富的专家分享真实世界的使用经验。

 

Oncology Frontier:At the 2026 SGO meeting，what research or topics do you think are most worthy of close attention?

 

Dong Hoon Suh:Undoubtedly，ADCs.Antibody-drug conjugates are now everywhere in gynecologic oncology.We included this topic in part 2 of our session as well(focus on systemic therapy).We invited Kosuke Shigematsu as the speaker to share his personal clinical experience.In Korea and Japan，we have not yet reached the same level of ADCs development—the market is still small，that sort of thing.Before introducing a new drug into daily clinical practice，we really want to listen to real-world experience from established experts.